Blood test could unlock new treatment for tough breast cancers
NCT ID NCT01975142
Summary
This study tested whether a blood test could find patients with metastatic breast cancer who might benefit from a targeted drug, even if their original tumor test suggested they wouldn't. Researchers looked for specific cancer cells in the blood of 155 patients whose cancer was classified as HER2-negative. If those cells were found, patients received the drug T-DM1 to see if it helped control their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER, HER2 NEGATIVE PRIMARY TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Catherine de Sienne
Vandœuvre-lès-Nancy, 54519, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Centre Val d'Aurelle - P. Lamarque
Montpellier, 34298, France
-
Chu Saint-Louis
Paris, 75475, France
-
Chu de Limoges
Limoges, 87042, France
-
Clinique Victor Hugo
Le Mans, 72000, France
-
Institut Curie
Paris, 75005, France
-
Institut Curie - Hôpital René HUGENIN
Saint-Cloud, SAINT-CLOUD, France
-
Institut de Cancérologie HARTMANN
Levallois-Perret, 92309, France
-
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, 54519, France
Conditions
Explore the condition pages connected to this study.